BioLineRx Ltd. (BLRX.TA)
ILA 1.7
(6.25%)
ILA 1.7
(6.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -42.17 Million USD | -77.93% |
| 2022 | -28.5 Million USD | 5.51% |
| 2021 | -24.07 Million USD | -4.89% |
| 2020 | -22.33 Million USD | 16.92% |
| 2019 | -26.88 Million USD | -0.13% |
| 2018 | -26.85 Million USD | -12.58% |
| 2017 | -23.85 Million USD | -46.95% |
| 2016 | -16.23 Million USD | 4.28% |
| 2015 | -15.77 Million USD | -78.17% |
| 2014 | -16.9 Million USD | 43.47% |
| 2013 | -16.68 Million USD | 21.28% |
| 2012 | -21.38 Million USD | -42.59% |
| 2011 | -15 Million USD | -325.04% |
| 2010 | 4.21 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 3.04 Million USD | 169.47% |
| 2024 Q1 | 1.13 Million USD | 107.99% |
| 2023 Q4 | -14.13 Million USD | 5.54% |
| 2023 Q2 | -17.01 Million USD | -54.97% |
| 2023 FY | - USD | -77.93% |
| 2023 Q3 | -14.96 Million USD | 12.02% |
| 2023 Q1 | -10.97 Million USD | -139.13% |
| 2022 Q2 | -6.92 Million USD | -51.45% |
| 2022 Q3 | -6.42 Million USD | 7.16% |
| 2022 Q4 | -4.59 Million USD | 28.58% |
| 2022 FY | - USD | 5.51% |
| 2022 Q1 | -4.57 Million USD | -15.78% |
| 2021 Q1 | -9.71 Million USD | 15.06% |
| 2021 Q2 | -6.42 Million USD | 33.89% |
| 2021 Q4 | -3.94 Million USD | 25.34% |
| 2021 FY | - USD | -4.89% |
| 2021 Q3 | -5.28 Million USD | 17.63% |
| 2020 Q2 | -6.16 Million USD | -4.26% |
| 2020 Q4 | -11.43 Million USD | -178.04% |
| 2020 FY | - USD | 16.92% |
| 2020 Q3 | -4.11 Million USD | 33.27% |
| 2020 Q1 | -5.91 Million USD | 36.11% |
| 2019 Q2 | -4.81 Million USD | 12.3% |
| 2019 Q1 | -5.49 Million USD | 33.87% |
| 2019 FY | - USD | -0.13% |
| 2019 Q3 | -3.11 Million USD | 35.4% |
| 2019 Q4 | -9.25 Million USD | -197.14% |
| 2018 Q2 | -4.62 Million USD | 20.9% |
| 2018 FY | - USD | -12.58% |
| 2018 Q4 | -8.31 Million USD | -34.31% |
| 2018 Q3 | -6.18 Million USD | -33.66% |
| 2018 Q1 | -5.85 Million USD | 28.28% |
| 2017 Q2 | -4.76 Million USD | -0.7% |
| 2017 Q1 | -4.73 Million USD | 2.57% |
| 2017 FY | - USD | -46.95% |
| 2017 Q4 | -8.16 Million USD | -14.83% |
| 2017 Q3 | -7.1 Million USD | -49.19% |
| 2016 Q3 | -4.2 Million USD | -16.63% |
| 2016 FY | - USD | 4.28% |
| 2016 Q1 | -3.36 Million USD | 38.18% |
| 2016 Q2 | -3.6 Million USD | -7.26% |
| 2016 Q4 | -4.85 Million USD | -15.4% |
| 2015 FY | - USD | -78.17% |
| 2015 Q4 | -5.44 Million USD | -286.36% |
| 2015 Q3 | -1.4 Million USD | 70.14% |
| 2015 Q2 | -4.71 Million USD | -12.48% |
| 2015 Q1 | -4.19 Million USD | 53.06% |
| 2014 Q3 | -1.62 Million USD | 61.18% |
| 2014 Q2 | -4.19 Million USD | -15.25% |
| 2014 FY | - USD | 43.47% |
| 2014 Q1 | -3.64 Million USD | -25.23% |
| 2014 Q4 | -8.93 Million USD | -448.3% |
| 2013 Q2 | -3.72 Million USD | 39.0% |
| 2013 Q1 | -6.1 Million USD | 31.89% |
| 2013 Q4 | -2.9 Million USD | 6.53% |
| 2013 FY | - USD | 21.28% |
| 2013 Q3 | -3.11 Million USD | 16.44% |
| 2012 FY | - USD | -42.59% |
| 2012 Q3 | -4.41 Million USD | 22.26% |
| 2012 Q2 | -5.68 Million USD | -16.51% |
| 2012 Q1 | -4.87 Million USD | -16.39% |
| 2012 Q4 | -8.96 Million USD | -102.89% |
| 2011 Q1 | -2.75 Million USD | 43.42% |
| 2011 Q3 | -4.5 Million USD | -5.19% |
| 2011 Q4 | -4.18 Million USD | 7.09% |
| 2011 FY | - USD | -325.04% |
| 2011 Q2 | -4.28 Million USD | -55.37% |
| 2010 Q1 | -3.82 Million USD | 0.0% |
| 2010 Q2 | -7.83 Million USD | -104.67% |
| 2010 Q3 | 20.99 Million USD | 368.09% |
| 2010 Q4 | -4.87 Million USD | -123.23% |
| 2010 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Matricelf Ltd | -11.51 Million ILA | -266.331% |